Your browser doesn't support javascript.
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
Zhou, Zehua; Zhang, Xinyu; Li, Qianqian; Fu, Lili; Wang, Meiyu; Liu, Shuo; Wu, Jiajing; Nie, Jianhui; Zhang, Li; Zhao, Chenyan; Jiang, Fei; An, Yimeng; Yu, Bin; Zheng, Haifa; Wang, Youchun; Zhao, Aihua; Huang, Weijin.
  • Zhou Z; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China; Beijing Minhai Biotechnology Co., Ltd, China.
  • Zhang X; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China; College of Life Science, Jilin University, Changchun, China.
  • Li Q; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Fu L; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Wang M; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Liu S; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Wu J; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Nie J; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Zhang L; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Zhao C; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Jiang F; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • An Y; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China.
  • Yu B; College of Life Science, Jilin University, Changchun, China.
  • Zheng H; Beijing Minhai Biotechnology Co., Ltd, China.
  • Wang Y; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: wangyc@nifdc.org.cn.
  • Zhao A; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: tbtestlab@nifdc.org.cn.
  • Huang W; Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: huangweijin@nifdc.org.cn.
Vaccine ; 39(41): 6050-6056, 2021 10 01.
Article in English | MEDLINE | ID: covidwho-1386708
ABSTRACT
The development of an effective vaccine to control the global coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) is of utmost importance. In this study, a synthetic DNA-based vaccine candidate, known as pSV10-SARS-CoV-2, expressing the SARS-CoV-2 spike protein was designed and tested in 39 BALB/c mice with BC01, an adjuvant derived from unmethylated CpG motif-containing DNA fragments from the Bacillus Calmette-Guerin genome. Mice vaccinated with pSV10-SARS-CoV-2 with BC01 produced early neutralizing antibodies and developed stronger humoral and cellular immune responses compared to mice that received the DNA vaccine only. Moreover, sera from mice vaccinated with pSV10-SARS-CoV-2 with BC01 can neutralize certain variants, including 614G, 614G + 472 V, 452R, 483A, 501Y.V2, and B.1.1.7. The results of this study demonstrate that the addition of BC01 to a DNA-vaccine for COVID-19 could elicit more effective neutralizing antibody titers for disease prevention.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, DNA / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2021.08.103

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, DNA / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2021.08.103